Base de dados : MEDLINE
Pesquisa : B04.280.382.150.150 [Categoria DeCS]
Referências encontradas : 19035 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1904 ir para página                         

  1 / 19035 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29377953
[Au] Autor:Waduthantri S; Zhou L; Chee SP
[Ad] Endereço:Singapore Eye Research Institute, Singapore, Singapore.
[Ti] Título:Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: A pilot study.
[So] Source:PLoS One;13(1):e0191850, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To investigate the intra-cameral level of ganciclovir following topical application of ganciclovir gel, 0.15% for cytomegalovirus (CMV) anterior segment infection. DESIGN: Non-randomized, prospective, interventional clinical study. METHODS: Patients with active CMV anterior segment infection seen at Singapore National Eye Centre, confirmed by positive CMV real time PCR (RT-PCR) of the aqueous humor, that had not been treated with any form of ganciclovir in the preceding 1 month were recruited. They were treated with ganciclovir gel, 0.15% 1cc 5 times a day. Following 6 weeks of treatment, CMV load in the aqueous humor was measured using CMV RT-PCR and the ganciclovir drug levels in tears and aqueous humor were measured using high-performance liquid chromatography-mass spectrometry. The clinical features of the disease activity and the central corneal thickness (CCT) were recorded at the baseline and post-treatment. RESULTS: There were 29 eyes of 29 patients, of which 23 eyes had CMV anterior uveitis and 6 eyes had CMV endotheliitis. At the end of week 6, 26 eyes had undetectable CMV titre in the aqueous humor and no anterior chamber (AC) activity. Two patients had an increased CMV titre and increased AC inflammation. Both of these patients were non-compliant with the treatment. One patient had a reduced CMV titre in the aqueous humor with minimal AC inflammation. The mean ganciclovir concentration in the aqueous humor and the tears were 17.4 ± 30.6 ng/ml and 20,420.9 ± 33,120.8 ng/ml respectively. Mean CCT was 552.2 ± 42.3 microns. There was a weak correlation between the ganciclovir concentration in the aqueous humor and CCT (Spearmen's r = + 0.42, p = 0.025). There was no significant correlation between the ganiclovir concentration in the tears and CCT (Spearmen's r = + 0.39, p = 0.11). CONCLUSION: Ganciclovir levels in the aqueous humor was below the 50% inhibitory dose (ID50) for CMV replication, following topical application of the ganciclovir gel, 0.15%. TRIAL REGISTRATION: SingHealth Centralized Institutional Review Board, Singapore; R733/17/2010, ClinicalTrials.gov; NCT01647529.
[Mh] Termos MeSH primário: Segmento Anterior do Olho/patologia
Antivirais/administração & dosagem
Infecções por Citomegalovirus/tratamento farmacológico
Ganciclovir/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oftálmica
Adulto
Idoso
Idoso de 80 Anos ou mais
Cromatografia Líquida
Citomegalovirus/genética
Feminino
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Estudos Prospectivos
Reação em Cadeia da Polimerase em Tempo Real
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:CLINICAL STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiviral Agents); P9G3CKZ4P5 (Ganciclovir)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191850


  2 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29211658
[Au] Autor:Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
[Ad] Endereço:From the Dana-Farber Cancer Institute and Brigham and Women's Hospital (F.M.M.) and Tufts Medical Center and Tufts University School of Medicine (D.R.S.), Boston; Karolinska University Hospital and Karolinska Institutet, Stockholm (P.L.); University of Texas M.D. Anderson Cancer Center, Houston (R.F
[Ti] Título:Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
[So] Source:N Engl J Med;377(25):2433-2444, 2017 12 21.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. METHODS: In this phase 3, double-blind trial, we randomly assigned CMV-seropositive transplant recipients, 18 years of age or older, in a 2:1 ratio to receive letermovir or placebo, administered orally or intravenously, through week 14 after transplantation; randomization was stratified according to trial site and CMV disease risk. Letermovir was administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). Patients in whom clinically significant CMV infection (CMV disease or CMV viremia leading to preemptive treatment) developed discontinued the trial regimen and received anti-CMV treatment. The primary end point was the proportion of patients, among patients without detectable CMV DNA at randomization, who had clinically significant CMV infection through week 24 after transplantation. Patients who discontinued the trial or had missing end-point data at week 24 were imputed as having a primary end-point event. Patients were followed through week 48 after transplantation. RESULTS: From June 2014 to March 2016, a total of 565 patients underwent randomization and received letermovir or placebo beginning a median of 9 days after transplantation. Among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group than in the placebo group had clinically significant CMV infection or were imputed as having a primary end-point event by week 24 after transplantation (122 of 325 patients [37.5%] vs. 103 of 170 [60.6%], P<0.001). The frequency and severity of adverse events were similar in the two groups overall. Vomiting was reported in 18.5% of the patients who received letermovir and in 13.5% of those who received placebo; edema in 14.5% and 9.4%, respectively; and atrial fibrillation or flutter in 4.6% and 1.0%, respectively. The rates of myelotoxic and nephrotoxic events were similar in the letermovir group and the placebo group. All-cause mortality at week 48 after transplantation was 20.9% among letermovir recipients and 25.5% among placebo recipients. CONCLUSIONS: Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo. Adverse events with letermovir were mainly of low grade. (Funded by Merck; ClinicalTrials.gov number, NCT02137772 ; EudraCT number, 2013-003831-31 .).
[Mh] Termos MeSH primário: Acetatos/uso terapêutico
Antivirais/uso terapêutico
Infecções por Citomegalovirus/prevenção & controle
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Quinazolinas/uso terapêutico
[Mh] Termos MeSH secundário: Acetatos/efeitos adversos
Adolescente
Adulto
Idoso
Antivirais/efeitos adversos
Citomegalovirus/genética
Citomegalovirus/isolamento & purificação
Infecções por Citomegalovirus/epidemiologia
Infecções por Citomegalovirus/etiologia
DNA Viral/sangue
Método Duplo-Cego
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Quinazolinas/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (AIC246); 0 (Acetates); 0 (Antiviral Agents); 0 (DNA, Viral); 0 (Quinazolines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171207
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1706640


  3 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453840
[Au] Autor:Young VP; Mariano MC; Tu CC; Allaire KM; Avdic S; Slobedman B; Spencer JV
[Ad] Endereço:Department of Biology, University of San Francisco, California, USA.
[Ti] Título:Modulation of the Host Environment by Human Cytomegalovirus with Viral Interleukin 10 in Peripheral Blood.
[So] Source:J Infect Dis;215(6):874-882, 2017 03 15.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Human cytomegalovirus (HCMV) is a herpesvirus with both lytic and latent life cycles. Human cytomegalovirus encodes 2 viral cytokines that are orthologs of human cellular interleukin 10 (cIL-10). Both cytomegalovirus interleukin 10 (cmvIL-10) and Latency-associated cytomegalovirus interleukin 10 (LAcmvIL-10) (collectively vIL-10) are expressed during lytic infection and cause immunosuppressive effects that impede virus clearance. LAcmvIL-10 is also expressed during latent infection of myeloid progenitor cells and monocytes and facilitates persistence. Here, we investigated whether vIL-10 could be detected during natural infection. Methods: Plasma from healthy blood donors was tested by enzyme-linked immunosorbent assay for anti-HCMV immunoglobulin G and immunoglobulin M and for cIL-10 and vIL-10 levels using a novel vIL-10 assay that detects cmvIL-10 and LAcmvIL-10, with no cross-reactivity to cIL-10. Results: vIL-10 was evident in HCMV+ donors (n = 19 of 26), at levels ranging 31-547 pg/mL. By comparison, cIL-10 was detected at lower levels ranging 3-69 pg/mL. There was a strong correlation between vIL-10 and cIL-10 levels (P = .01). Antibodies against vIL-10 were also detected and neutralized vIL-10 activity. Conclusions: vIL-10 was detected in peripheral blood of healthy blood donors. These findings suggest that vIL-10 may play a key role in sensing or modifying the host environment during latency and, therefore, may be a potential target for intervention strategies.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/sangue
Citomegalovirus/imunologia
Interleucina-10/sangue
Proteínas Virais/sangue
[Mh] Termos MeSH secundário: Anticorpos Antivirais/sangue
Reações Cruzadas
Infecções por Citomegalovirus/imunologia
Ensaio de Imunoadsorção Enzimática
Voluntários Saudáveis
Seres Humanos
Tolerância Imunológica
Imunoglobulina G/sangue
Imunoglobulina M/sangue
Interleucina-10/imunologia
Monócitos/imunologia
Proteínas Virais/imunologia
Latência Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (CMV IL-10 protein, Cytomegalovirus); 0 (Immunoglobulin G); 0 (Immunoglobulin M); 0 (Viral Proteins); 130068-27-8 (Interleukin-10)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix043


  4 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29257134
[Au] Autor:Balázs Z; Tombácz D; Szucs A; Snyder M; Boldogkoi Z
[Ad] Endereço:Department of Medical Biology, Faculty of Medicine, University of Szeged, Szeged 6720, Hungary.
[Ti] Título:Long-read sequencing of the human cytomegalovirus transcriptome with the Pacific Biosciences RSII platform.
[So] Source:Sci Data;4:170194, 2017 12 19.
[Is] ISSN:2052-4463
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Long-read RNA sequencing allows for the precise characterization of full-length transcripts, which makes it an indispensable tool in transcriptomics. The human cytomegalovirus (HCMV) genome has been first sequenced in 1989 and although short-read sequencing studies have uncovered much of the complexity of its transcriptome, only few of its transcripts have been fully annotated. We hereby present a long-read RNA sequencing dataset of HCMV infected human lung fibroblast cells sequenced by the Pacific Biosciences RSII platform. Seven SMRT cells were sequenced using oligo(dT) primers to reverse transcribe poly(A)-selected RNA molecules and one library was prepared using random primers for the reverse transcription of the rRNA-depleted sample. Our dataset contains 122,636 human and 33,086 viral (HMCV strain Towne) reads. The described data include raw and processed sequencing files, and combined with other datasets, they can be used to validate transcriptome analysis tools, to compare library preparation methods, to test base calling algorithms or to identify genetic variants.
[Mh] Termos MeSH primário: Citomegalovirus/genética
Transcriptoma
[Mh] Termos MeSH secundário: Perfilação da Expressão Gênica
Genoma Viral
Análise de Sequência de RNA
[Pt] Tipo de publicação:DATASET; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE
[do] DOI:10.1038/sdata.2017.194


  5 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28451898
[Au] Autor:Liu XJ; Jiang X; Huang SN; Sun JY; Zhao F; Zeng WB; Luo MH
[Ad] Endereço:State Key Laboratory of Virology, CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT), Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
[Ti] Título:Human cytomegalovirus infection dysregulates neural progenitor cell fate by disrupting Hes1 rhythm and down-regulating its expression.
[So] Source:Virol Sin;32(3):188-198, 2017 Jun.
[Is] ISSN:1995-820X
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:Human cytomegalovirus (HCMV) infection is a leading cause of birth defects, primarily affecting the central nervous system and causing its maldevelopment. As the essential downstream effector of Notch signaling pathway, Hes1, and its dynamic expression, plays an essential role on maintaining neural progenitor /stem cells (NPCs) cell fate and fetal brain development. In the present study, we reported the first observation of Hes1 oscillatory expression in human NPCs, with an approximately 1.5 hour periodicity and a Hes1 protein half-life of about 17 (17.6 ± 0.2) minutes. HCMV infection disrupts the Hes1 rhythm and down-regulates its expression. Furthermore, we discovered that depleting Hes1 protein disturbed NPCs cell fate by suppressing NPCs proliferation and neurosphere formation, and driving NPCs abnormal differentiation. These results suggested a novel mechanism linking disruption of Hes1 rhythm and down-regulation of Hes1 expression to neurodevelopmental disorders caused by congenital HCMV infection.
[Mh] Termos MeSH primário: Citomegalovirus/fisiologia
Interações Hospedeiro-Patógeno
Células-Tronco Neurais/fisiologia
Células-Tronco Neurais/virologia
Fatores de Transcrição HES-1/biossíntese
[Mh] Termos MeSH secundário: Diferenciação Celular
Proliferação Celular
Células Cultivadas
Regulação para Baixo
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Transcription Factor HES-1); 149348-15-2 (HES1 protein, human)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1007/s12250-017-3956-0


  6 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773685
[Au] Autor:Fehniger TA; Cooper MA
[Ad] Endereço:Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: tfehnige@wustl.edu.
[Ti] Título:Harnessing NK Cell Memory for Cancer Immunotherapy.
[So] Source:Trends Immunol;37(12):877-888, 2016 12.
[Is] ISSN:1471-4981
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Due to their ability to kill cancer cells and produce proinflammatory cytokines, natural killer (NK) cells have long been of clinical interest for their antitumor properties. The recent discovery of NK cell memory demonstrates that NK cell functions, and potentially antitumor responses, can be enhanced long term. Following nonspecific activation with the cytokines IL-12, IL-15, and IL-18 or in response to antigens or cytomegalovirus (CMV), human and mouse NK cells exhibit stable, enhanced functional responses with phenotypic and molecular changes. Here we review mechanisms driving the differentiation of NK cell memory-like properties, evidence for antitumor activity, and the challenges and opportunities in harnessing memory-like NK cells for cancer immunotherapy.
[Mh] Termos MeSH primário: Vacinas Anticâncer/imunologia
Memória Imunológica
Imunoterapia Adotiva/métodos
Células Matadoras Naturais/imunologia
Subpopulações de Linfócitos/imunologia
Neoplasias/terapia
[Mh] Termos MeSH secundário: Animais
Diferenciação Celular
Citocinas/metabolismo
Citomegalovirus/imunologia
Citotoxicidade Imunológica
Seres Humanos
Mediadores da Inflamação/metabolismo
Células Matadoras Naturais/transplante
Ativação Linfocitária
Subpopulações de Linfócitos/transplante
Camundongos
Neoplasias/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (Cytokines); 0 (Inflammation Mediators)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  7 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29422759
[Au] Autor:Parchand S; Barwad A
[Ad] Endereço:Department of Ophthalmology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
[Ti] Título:Cytomegalovirus Retinitis as a Presenting Feature of Multisystem Disorder: Dyskeratosis Congenita.
[So] Source:Middle East Afr J Ophthalmol;24(4):219-221, 2017 Oct-Dec.
[Is] ISSN:0975-1599
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Cytomegalovirus (CMV) retinitis is an opportunistic infection commonly seen in disorders that affect the immune system of the body such as acquired immunodeficiency syndrome and hematological malignancies such as leukemia/lymphoma or organ transplantation. The occurrence of CMV retinitis in the absence of such condition should be thoroughly investigated, as it is a strong indicator of poor immune competence. We here report an interesting case of CMV retinitis as a presenting feature of rare multisystem disorde "Dyskeratosis congenita."
[Mh] Termos MeSH primário: Retinite por Citomegalovirus/diagnóstico
Disceratose Congênita/diagnóstico
[Mh] Termos MeSH secundário: Antivirais/uso terapêutico
Biópsia
Citomegalovirus/isolamento & purificação
Retinite por Citomegalovirus/tratamento farmacológico
Citometria de Fluxo
Ganciclovir/análogos & derivados
Ganciclovir/uso terapêutico
Gastrectomia
Seres Humanos
Hibridização in Situ Fluorescente
Masculino
Meia-Idade
Corpo Vítreo/virologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); GCU97FKN3R (valganciclovir); P9G3CKZ4P5 (Ganciclovir)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE
[do] DOI:10.4103/meajo.MEAJO_230_15


  8 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29297219
[Au] Autor:Lucenko MT; Andrievskaya IA; Dolzhikova IV
[Ti] Título:Energy Metabolism in the Placenta and the Role of Disturbances in the Development of Placental Insufficiency at an Exacerbation of Cytomegalovirus Infection.
[So] Source:Vestn Ross Akad Med Nauk;71(3):177-82, 2016.
[Is] ISSN:0869-6047
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:Objective: Determine the characteristics of placental energy metabolism and to establish its role in the development of placental insufficiency at an exacerbation of cytomegalovirus (CMV) infection in 25­28 weeks of gestation. Methods: In a prospective study of the case-control type included pregnant, delivery on term of 37­38 weeks. The sample of 50 pregnant women, including 25 CMV-seropositive with exacerbation of CMV infection at 25­28 weeks of gestation and with the titer of IgG antibodies to CMV 1: 1600 at the time of the study and 25 CMV-seronegative women the same pregnancy. The study was conducted at the obstetric department of pathology of pregnancy and laboratory «Etiopathogenesis mechanisms and recovery processes with non-specific lung diseases¼ Far Eastern Scientific Center of Physiology and Pathology of Respiration together with the urban maternity ward at City Hospital in the period from 2014 to 2015. The activity of pyruvate dehydrogenase, α-ketoglutarate dehydrogenase and a dehydrogenase lipoic acid was determined by histochemical methods on cryostat sections of fresh frozen tissue placenta by the method of R. Lilly. Evaluation of the intensity of histochemical reactions carried out by the program cytophotometry Scion. The morphology of the placenta was studied in paraffin sections stained with hematoxylin Böhmer-eosin, van Gieson's picrofuchsin and alcian blue by Steedman. Results: Exacerbation of CMV infection at 25­28 weeks of gestation leads to a decrease in the intensity of the histochemical reaction of pyruvate dehydrogenase in 2.4 times, lipoic acid dehydrogenase ­ in 2.9 times, and α-ketoglutarate dehydrogenase ­ in 1.5 times in the syncytiotrophoblast villous placenta. The placental morphological structure study showed villi in a state of death or necrotic changes, as well as increasing the number of avascular immature villi. In the maternal part of the placenta were marked constriction clearances, hypertrophy of muscle and connective tissue layers blood vessels. Conclusion: The findings suggest that the exacerbation of CMV infection at 25­28 weeks of pregnancy causes a decrease in the intensity of energy metabolism in the placenta by suppressing the activity of the enzymes α-ketoglutarate dehydrogenase and pyruvate dehydrogenase complex, which is accompanied by disturbances of the morphological structure of the placental barrier, the development of placental insufficiency.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus
Complexo Cetoglutarato Desidrogenase/metabolismo
Insuficiência Placentária/metabolismo
Complicações Infecciosas na Gravidez
Complexo Piruvato Desidrogenase/metabolismo
Trofoblastos
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Citomegalovirus/isolamento & purificação
Infecções por Citomegalovirus/diagnóstico
Infecções por Citomegalovirus/metabolismo
Infecções por Citomegalovirus/fisiopatologia
Metabolismo Energético
Feminino
Seres Humanos
Insuficiência Placentária/diagnóstico
Gravidez
Complicações Infecciosas na Gravidez/diagnóstico
Complicações Infecciosas na Gravidez/metabolismo
Complicações Infecciosas na Gravidez/fisiopatologia
Estatística como Assunto
Trofoblastos/metabolismo
Trofoblastos/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pyruvate Dehydrogenase Complex); EC 1.2.4.2 (Ketoglutarate Dehydrogenase Complex)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE


  9 / 19035 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Colômbia
Texto completo SciELO Saúde Pública
[PMID]:28453063
[Au] Autor:Tique V; Mattar S; Freire M; Illian E; Camargo F; Vergara O; Moraes-Figueiredo LT
[Ad] Endereço:Universidad de Cordoba, Monteria, Colombia, overgara@correo.unicordoba.edu.co.
[Ti] Título:Epidemiological surveillance of herpes viral encephalitis in Cordoba, Colombia.
[So] Source:Rev Salud Publica (Bogota);18(4):581-591, 2016 Aug.
[Is] ISSN:0124-0064
[Cp] País de publicação:Colombia
[La] Idioma:eng
[Ab] Resumo:Objective To establish an epidemiological surveillance of viral herpes encephalitis in major hospitals of Monteria, Cordoba. Methods From September 2009 to December 2011, a descriptive study of cases of viral encephalitis was made in three hospitals in the city of Monteria. Cerebrospinal fluid (CSF) samples from 118 patients were included in the study. Clinical aspects, as well as cytochemical and microbiological analysis (Gram stain and culture) of CSF, were used for selecting the patients. Virus detection was performed by using multiplex nested PCR for Herpes simplex virus 1 and 2, Epstein Barr virus, Cytomegalovirus and Varicella zoster virus. Results Viral DNA of herpesvirus was detected in the CSFs of 30 (25.4 %) participants, as follows: 22 (18.6 %) Herpes simplex 1 and 2 viruses, 4 (3.3 %) Cytomegalovirus and 1 (0.8 %) Varicella zoster virus. Co-infections were observed in 3 patients (2.5 %), 1 case by HSV-VZV and 2 cases by CMV/HSV. The clinical manifestations of the patients included: headache (18.6 %), fever (14.4 %), asthenia (10.1 %), seizures (9.3 %), vomiting (8.4 %), and stiff neck (5.9 %). Thirty percent of the patients also had HIV-AIDS. A case fatality rate of 20 % was observed for the patients. Conclusions This paper shows that herpesvirus is a cause of infection of the CNS in patients from Cordoba. This study contributes to the epidemiology of encephalitis, as well as to patient management.
[Mh] Termos MeSH primário: Encefalite Viral/epidemiologia
Infecções por Herpesviridae/epidemiologia
Vigilância da População
[Mh] Termos MeSH secundário: Coinfecção/líquido cefalorraquidiano
Coinfecção/epidemiologia
Coinfecção/virologia
Colômbia/epidemiologia
Citomegalovirus/isolamento & purificação
Infecções por Citomegalovirus/líquido cefalorraquidiano
Infecções por Citomegalovirus/epidemiologia
Encefalite por Herpes Simples/líquido cefalorraquidiano
Encefalite por Herpes Simples/epidemiologia
Encefalite por Varicela Zoster/líquido cefalorraquidiano
Encefalite por Varicela Zoster/epidemiologia
Encefalite Viral/líquido cefalorraquidiano
Infecções por Herpesviridae/líquido cefalorraquidiano
Herpesvirus Humano 3
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  10 / 19035 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454912
[Au] Autor:Pertusati F; Serafini S; Albadry N; Snoeck R; Andrei G
[Ad] Endereço:School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, CF10 3NB, Cardiff, Wales, United Kingdom. Electronic address: pertusatif1@cardiff.ac.uk.
[Ti] Título:Phosphonoamidate prodrugs of C5-substituted pyrimidine acyclic nucleosides for antiviral therapy.
[So] Source:Antiviral Res;143:262-268, 2017 07.
[Is] ISSN:1872-9096
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Acyclic nucleoside phosphonates (ANPs) are nowadays one of the key drugs in the treatment of DNA virus and retrovirus infections. In this work, we report the synthesis and antiviral evaluation of phosphonoamidate and diamidates prodrugs of C5-pyrimidine acyclic nucleosides derivatives functionalized with but-2-enyl- chain. In the phosphonoamidate series, the most active compound 15, showed sub-micromolar activity against varicella zoster virus (VZV) (EC = 0.09-0.5 µM) and µM activity against human cytomegalovirus (HCMV) and herpes simplex virus (HSV). Separation of single diastereoisomers for compound 14, showed that 14b had better anti-herpesvirus activity and no cytotoxicity compared to the diastereoisomeric mixture 14. Very interestingly, phosphonodiamidate 21 showed anti-herpesvirus activity with excellent activity against wild type and thymidine kinase-deficient (TK ) VZV strains (EC = 0.47 and 0.2 µM, respectively) and HCMV (EC = 3.5-7.2 µM) without any cytotoxicity (CC > 100).
[Mh] Termos MeSH primário: Pró-Fármacos/síntese química
Pró-Fármacos/farmacologia
Nucleosídeos de Pirimidina/síntese química
Nucleosídeos de Pirimidina/farmacologia
[Mh] Termos MeSH secundário: Antivirais/síntese química
Antivirais/farmacologia
Linhagem Celular
Citomegalovirus/efeitos dos fármacos
Herpesvirus Humano 3/efeitos dos fármacos
Seres Humanos
Simplexvirus/efeitos dos fármacos
Timidina Quinase
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Prodrugs); 0 (Pyrimidine Nucleosides); EC 2.7.1.21 (Thymidine Kinase)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE



página 1 de 1904 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde